We are live on ! Find out more
PI

Pharmstandard International Portfolio holdings

AUM $29M
1-Year Est. Return 3.25%
This Fund
S&P 500
This Quarter Est. Return
+20.4%
1 Year Est. Return
+3.25%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$39.8M
AUM Growth
-$57.5M
Cap. Flow
+$316K
Cap. Flow %
0.79%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ARGS
Argos Therapeutics, Inc.
ARGS
+$316K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 99.42%
2 Miscellaneous 0.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JNCE
1
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$14.8M 37.17%
662,063
– –
ALNA
2
DELISTED
Allena Pharmaceuticals
ALNA
$11.4M 28.71%
1,037,267
– –
PTGX icon
3
Protagonist Therapeutics
PTGX
$9.67B
$8.44M 21.2%
982,270
– –
TARA icon
4
Protara Therapeutics
TARA
$236M
$4.17M 10.47%
41,698
– –
ARGS
5
DELISTED
Argos Therapeutics, Inc.
ARGS
$744K 1.87%
826,153
+169,014
+26% +$316K
ARGS
6
CALL
DELISTED
Argos Therapeutics, Inc.
ARGS
$230K 0.58%
256,030
– –

Similar funds

IP
Ironsides Partners Boston, Massachusetts $27.7M AUM 1.11% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
MC
Marcus Capital Northbrook, Illinois $34.3M AUM 30.44% 1-Year Est. Return
RIA
Rocaton Investment Advisors Norwalk, Connecticut $36.6M AUM 10.31% 1-Year Est. Return
FC
Flaherty & Crumrine Pasadena, California $19.8M AUM 3.53% 1-Year Est. Return
WFC
West Face Capital Toronto, Ontario, Canada $16.6M AUM 18.79% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
DCM
Dearborn Capital Management Chicago, Illinois $41.6M AUM 2.79% 1-Year Est. Return

Pharmstandard International's Q1 2018 Portfolio in Review

As of Q1 2018, Pharmstandard International held 6 positions worth $39.8M, down 59% from $97.3M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2018: portfolio turnover was 0%. Pharmstandard International opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 84% a quarter earlier, followed by Miscellaneous.

  • Pharmstandard International added most to Argos Therapeutics, Inc. in Q1 2018, an estimated $316K increase.
  • Pharmstandard International's ten largest holdings make up 100% of its $39.8M portfolio in Q1 2018.
  • Pharmstandard International opened 0 new positions and closed 0 in Q1 2018.
  • Pharmstandard International's portfolio value fell 59% quarter-over-quarter to $39.8M.

Based on Pharmstandard International's 13F filing for Q1 2018, filed 15 May 2018.